Published in Healthcare Finance, Tax and Law Weekly, February 7th, 2007
Under terms of the agreement, PreMD has entered into an amendment of the existing licensing agreement relating to two existing U.S. and Japanese patents for a technology that detects a carbohydrate marker associated with cancerous and pre-cancerous conditions. The new arrangements reduce the royalty payable by PreMD to 7.5% from 10% on its revenues...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.